Colonization and infection with extended-spectrum beta-lactamase producing Enterobacteriaceae in patients with malignancy

References

• Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18:657–686. Epub 2005 Oct 15.
   PubMed Web of Science ®Google Scholar
• Brolund A, Sandegren L. Characterization of ESBL disseminating plasmids. Infectious Diseases (London, England). 2016;48:18–25. Epub 2015 Jul 03.
   PubMed Web of Science ®Google Scholar
• Calbo E, Garau J. The changing epidemiology of hospital outbreaks due to ESBL-producing Klebsiella pneumoniae: the CTX-M-15 type consolidation. Future Microbiol. 2015;10:1063–1075. Epub 2015 Jun 11.
   PubMed Web of Science ®Google Scholar
• Pitout JD. Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs. 2010;70:313–333. Epub 2010 Feb 20.
   PubMed Web of Science ®Google Scholar
• D’Angelo RG, Johnson JK, Bork JT, et al. Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria. Expert Opin Pharmacother. 2016;17:953–967. Epub 2016/02/20.
   PubMed Web of Science ®Google Scholar
• Trecarichi EM, Cauda R, Tumbarello M. Detecting risk and predicting patient mortality in patients with extended-spectrum beta-lactamase-producing Enterobacteriaceae bloodstream infections. Future Microbiol. 2012;7:1173–1189. Epub 2012 Oct 04.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Spanu T, Di Bidino R, et al. Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother. 2010;54:4085–4091. Epub 2010/07/28.
   PubMed Web of Science ®Google Scholar
• Rottier WC, Ammerlaan HS, Bonten MJ. Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis. J Antimicrob Chemother. 2012;67:1311–1320. Epub 2012 Mar 08.
   PubMed Web of Science ®Google Scholar
• Biehl LM, Schmidt-Hieber M, Liss B, et al. Colonization and infection with extended spectrum beta-lactamase producing Enterobacteriaceae in high-risk patients - Review of the literature from a clinical perspective. Crit Rev Microbiol. 2016;42:1–16. Epub 2014 Feb 06.
   PubMed Web of Science ®Google Scholar
• Palzkill T. Metallo-beta-lactamase structure and function. Ann N Y Acad Sci. 2013;1277:91–104. Epub 2012 Nov 21.
   PubMed Web of Science ®Google Scholar
• Canton R, Coque TM. The CTX-M beta-lactamase pandemic. Curr Opin Microbiol. 2006;9:466–475. Epub 2006 Sep 01.
   PubMed Web of Science ®Google Scholar
• D’Andrea MM, Arena F, Pallecchi L, et al. CTX-M-type beta-lactamases: a successful story of antibiotic resistance. Int J Med Microbiol. 2013;303:305–317. Epub 2013 Mar 16.
   PubMed Web of Science ®Google Scholar
• European Committee on Antimicrobial Susceptibility Testing. EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. 2013 [cited 2016 15 Apr]. Available from: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Consultation/EUCAST_guidelines_detection_of_resistance_mechanisms_121222.pdf
   Google Scholar
• Madec JY, Haenni M, Nordmann P, et al. ESBL/AmpC- and carbapenemase-producing Enterobacteriaceae in animals: a threat for humans? Clin Microbiol Infect. 2017. Epub 2017 Feb 02
   PubMedGoogle Scholar
• Karanika S, Karantanos T, Arvanitis M, et al. Fecal colonization with extended-spectrum beta-lactamase-producing enterobacteriaceae and risk factors among healthy individuals: a systematic review and meta-analysis. Clin Infect Dis;2016. Epub 2016 May 05.
   Web of Science ®Google Scholar
• Bar-Yoseph H, Hussein K, Braun E, et al. Natural history and decolonization strategies for ESBL/carbapenem-resistant Enterobacteriaceae carriage: systematic review and meta-analysis. J Antimicrob Chemother. 2016;71:2729–2739. Epub 2016 Jun 19.
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention. Biggest Threats. 2013 [cited 2016 1 Apr] Available from: http://www.cdc.gov/drugresistance/biggest_threats.html
   Google Scholar
• Castanheira M, Farrell SE, Krause KM, et al. Contemporary diversity of beta-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent beta-lactamase groups. Antimicrob Agents Chemother. 2014;58:833–838. Epub 2013 Nov 20.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net), 2015 2017 [cited 2017 March 1]. Available from: http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-europe-2015.pdf
   Google Scholar
• Morrissey I, Hackel M, Badal R, et al. A review of ten years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. Pharmaceuticals (Basel, Switzerland). 2013;6:1335–1346. Epub 2013 Nov 30.
   PubMedGoogle Scholar
• Jean SS, Hsueh PR. High burden of antimicrobial resistance in Asia. Int J Antimicrob Agents. 2011;37:291–295. Epub 2011/03/09.
   PubMed Web of Science ®Google Scholar
• Sonda T, Kumburu H, van Zwetselaar M, et al. Meta-analysis of proportion estimates of Extended-Spectrum-Beta-Lactamase-producing Enterobacteriaceae in East Africa hospitals. Antimicrob Resist Infect Control. 2016;5:18. Epub 2016/05/18.
   PubMed Web of Science ®Google Scholar
• Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med. 2005;352:380–391. Epub 2005/01/28.
   PubMed Web of Science ®Google Scholar
• Kang CI, Wi YM, Lee MY, et al. Epidemiology and risk factors of community onset infections caused by extended-spectrum beta-lactamase-producing Escherichia coli strains. J Clin Microbiol. 2012;50:312–317. Epub 2011 Dec 14.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bano J, Picon E, Gijon P, et al. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis. 2010;50:40–48. Epub 2009 Dec 10.
   PubMed Web of Science ®Google Scholar
• Detsis M, Karanika S, Mylonakis E. Epub 2017 Feb 06. ICU acquisition rate, risk factors, and clinical significance of digestive tract colonization with extended-spectrum beta-lactamase-producing enterobacteriaceae: a systematic review and meta-analysis. Crit Care Med. 2017;45:705–714.
   PubMed Web of Science ®Google Scholar
• Alevizakos M, Kallias A, Flokas ME, et al. Colonization with ESBL-producing enterobacteriaceae and risk for infection in solid organ transplantation: a systematic review and meta-analysis. Transpl Infect Dis (Accepted). 2017;e12718. Epub ahead of print.
   PubMedGoogle Scholar
• Winters HA, Parbhoo RK, Schafer JJ, et al. Extended-spectrum beta-lactamase-producing bacterial infections in adult solid organ transplant recipients. Ann Pharmacother. 2011;45:309–316. Epub 2011 Mar 10.
   PubMed Web of Science ®Google Scholar
• Yabanoglu H, Aliskan HE, Caliskan K, et al. Early infections in renal transplant recipients: incidence, risk factors, and causative microorganisms. Exp Clin Transplant. 2015;13 Suppl 3:11–14. Epub 2015 Dec 08.
   PubMed Web of Science ®Google Scholar
• Donskey CJ. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin Infect Dis. 2004;39:219–226. Epub 2004/08/13.
   PubMed Web of Science ®Google Scholar
• Montassier E, Gastinne T, Vangay P, et al. Chemotherapy-driven dysbiosis in the intestinal microbiome. Aliment Pharmacol Ther. 2015;42:515–528. Epub 2015 Jul 07.
   PubMed Web of Science ®Google Scholar
• van der Velden WJ, Herbers AH, Netea MG, et al. Mucosal barrier injury, fever and infection in neutropenic patients with cancer: introducing the paradigm febrile mucositis. Br J Haematol. 2014;167:441–452. Epub 2014 Sep 10.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bano J, Navarro MD, Romero L, et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol. 2004;42:1089–1094. Epub 2004 Mar 09.
   PubMed Web of Science ®Google Scholar
• Liss BJ, Vehreschild JJ, Cornely OA, et al. Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection. 2012;40:613–619. Epub 2012 Jun 06.
   PubMed Web of Science ®Google Scholar
• Vehreschild MJG, Peterson L, Schubert S, et al. A multicenter cohort study on colonization and infection with extended-spectrum beta-lactamase producing enterobacteriaceae (ESBL-E) in high-risk patients with hematological malignancies. Oncol Res Treat. 2014;37:121–122.
   Web of Science ®Google Scholar
• Dolejska M, Brhelova E, Dobiasova H, et al. Dissemination of IncFII(K)-type plasmids in multiresistant CTX-M-15-producing Enterobacteriaceae isolates from children in hospital paediatric oncology wards. Int J Antimicrob Agents. 2012;40:510–515. Epub 2012 Oct 10.
   PubMed Web of Science ®Google Scholar
• Kolar M, Htoutou Sedlakova M, Pudova V, et al. Incidence of fecal Enterobacteriaceae producing broad-spectrum beta-lactamases in patients with hematological malignancies. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159:100–103. Epub 2014 Oct 02.
   PubMed Web of Science ®Google Scholar
• Arnan M, Gudiol C, Calatayud L, et al. Risk factors for, and clinical relevance of, faecal extended-spectrum beta-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. Eur J Clin Microbiol Infect Dis. 2011;30:355–360. Epub 2010 Nov 06.
   PubMed Web of Science ®Google Scholar
• Calatayud L, Arnan M, Linares J, et al. Prospective study of fecal colonization by extended-spectrum-beta-lactamase-producing Escherichia coli in neutropenic patients with cancer. Antimicrob Agents Chemother. 2008;52:4187–4190. Epub 2008 Sep 24.
   PubMed Web of Science ®Google Scholar
• O’Connell N, Keating D, Kavanagh J, et al. Detection and characterization of extended-spectrum beta-lactamase-producing Enterobacteriaceae in high-risk patients in an Irish tertiary care hospital. J Hosp Infect. 2015;90:102–107. Epub 2015 Mar 24.
   PubMed Web of Science ®Google Scholar
• Kontopidou FV, Antoniadou A, Tsirigotis P, et al. The impact of an antimicrobial cycling strategy for febrile neutropenia in a haematology unit. J Chemother. 2013;25:279–285.
   PubMed Web of Science ®Google Scholar
• Chong Y, Shimoda S, Yakushiji H, et al. Clinical impact of fluoroquinolone-resistant Escherichia coli in the fecal flora of hematological patients with neutropenia and levofloxacin prophylaxis. PLoS One. 2014;9:e85210. Epub 2014 Jan 28.
   PubMed Web of Science ®Google Scholar
• Nurul Atifah MA, Loo HK, Subramaniam G, et al. Faecal prevalence of extended-spectrum Beta-lactamase (ESBL)-producing coliforms in a geriatric population and among haematology patients. Malays J Pathol. 2005;27:75–81. Epub 2006 Dec 29.
   PubMedGoogle Scholar
• Thacker N, Pereira N, Banavali SD, et al. Alarming prevalence of community-acquired multidrug-resistant organisms colonization in children with cancer and implications for therapy: a prospective study. Indian J Cancer. 2014;51:442–446. Epub 2014 Oct 01.
   PubMed Web of Science ®Google Scholar
• Medboua-Benbalagh C, Touati A, Kermas R, et al. Fecal carriage of extended-spectrum beta-lactamase-producing enterobacteriaceae strains is associated with worse outcome in patients hospitalized in the pediatric oncology unit of Beni-Messous Hospital in Algiers, Algeria. Microbial Drug Resistance (Larchmont, NY). 2017. Epub 2017 Jan 18
   PubMedGoogle Scholar
• Reddy P, Malczynski M, Obias A, et al. Screening for extended-spectrum beta-lactamase-producing Enterobacteriaceae among high-risk patients and rates of subsequent bacteremia. Clin Infect Dis. 2007;45:846–852. Epub 2007 Sep 07.
   PubMed Web of Science ®Google Scholar
• Alevizakos M, Karanika S, Detsis M, et al. Epub 2016 Oct 18. Colonisation with extended-spectrum beta-lactamase-producing Enterobacteriaceae and risk for infection among patients with solid or haematological malignancy: a systematic review and meta-analysis. Int J Antimicrob Agents. 2016;48:647–654.
   PubMed Web of Science ®Google Scholar
• Holmes AH, Moore LS, Sundsfjord A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet (London, England). 2016;387:176–187. Epub 2015 Nov 26.
   PubMed Web of Science ®Google Scholar
• Gudiol C, Calatayud L, Garcia-Vidal C, et al. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother. 2010;65:333–341. Epub 2009 Dec 05.
   PubMed Web of Science ®Google Scholar
• Cornejo-Juarez P, Suarez-Cuenca JA, Volkow-Fernandez P, et al. Fecal ESBL Escherichia coli carriage as a risk factor for bacteremia in patients with hematological malignancies. Supportive Care Cancer. 2016;24:253–259. Epub 2015 May 28.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Definition of region groupings 2016 [cited 2016 Oct 11]. Available from: http://www.who.int/healthinfo/global_burden_disease/definition_regions/en/
   Google Scholar
• Krenn T, Fleischhack G, Moser O, et al. Bloodstream infections in paediatric cancer patients. Prospective comparative study in 2 university hospitals. Klin Padiatr. 2011;223:335–340. Epub 2011 Oct 21.
   PubMed Web of Science ®Google Scholar
• Hallbook H, Lidstrom AK, Pauksens K. Ciprofloxacin prophylaxis delays initiation of broad-spectrum antibiotic therapy and reduces the overall use of antimicrobial agents during induction therapy for acute leukaemia: a single-centre study. Infectious Diseases (London, England). 2016;48:443–448. Epub 2016 Apr 01.
   PubMed Web of Science ®Google Scholar
• Bodro M, Gudiol C, Garcia-Vidal C, et al. Epidemiology, antibiotic therapy and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in cancer patients. Supportive Care Cancer. 2014;22:603–610. Epub 2013 Oct 31.
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Antoniazzi F, Tumbarello M, et al. Relapsing bloodstream infections during treatment of acute leukemia. Ann Hematol. 2014;93:785–790.
   PubMed Web of Science ®Google Scholar
• De Rosa FG, Motta I, Audisio E, et al. Epidemiology of bloodstream infections in patients with acute myeloid leukemia undergoing levofloxacin prophylaxis. BMC Infect Dis. 2013;13:563.
   PubMed Web of Science ®Google Scholar
• Aydemir H, Piskin N, Kokturk F, et al. Health-care associated bacteremia in geriatric cancer patients with febrile neutropenia. J Geriatr Oncol. 2013;4:190–195. Epub 2013 Sep 28.
   PubMed Web of Science ®Google Scholar
• Gedik H, Yildirmak T, Simsek F, et al. The outcome of non-carbapenem-based empirical antibacterial therapy and VRE colonisation in patients with hematological malignancies. Afr Health Sci. 2013;13:362–368. Epub 2013 Nov 16.
   PubMed Web of Science ®Google Scholar
• Kara Ö, Zarakolu P, Aşçioʇlu S, et al. Epidemiology and emerging resistance in bacterial bloodstream infections in patients with hematologic malignancies. Infect Dis. 2015;47:686–693.
   PubMed Web of Science ®Google Scholar
• Yemisen M, Balkan II, Salihoglu A, et al. The changing epidemiology of bloodstream infections and resistance in hematopoietic stem cell transplantation recipients. Turk J Haematol. 2016;33:216–222. Epub 2015 Apr 29.
   PubMed Web of Science ®Google Scholar
• Al-Sweedan SA, Hyajneh W, Al-Ostath A. Patterns of bacteremia in cancer patient with febrile neutropenia at King Abdullah University Hospital - Jordan 2003–2008. J Pediatr Infect Dis. 2012;7:15–20.
   Google Scholar
• Alshukairi A, Alserehi H, El-Saed A, et al. A de-escalation protocol for febrile neutropenia cases and its impact on carbapenem resistance: a retrospective, quasi-experimental single-center study. J Infect Public Health. 2015;9(4):443-451.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya A, Krishnan S, Saha V, et al. Microbiology, infection control and infection related outcome in pediatric patients in an oncology center in Eastern India: experience from Tata Medical Center, Kolkata. Indian J Cancer. 2014;51:415–417.
   PubMed Web of Science ®Google Scholar
• Reddy R, Pathania S, Kapil A, et al. Review of spectrum and sensitivity of bacterial bloodstream isolates in children with malignancy: a retrospective analysis from a single center. Indian J Cancer. 2014;51:425–427.
   PubMed Web of Science ®Google Scholar
• Siddaiahgari S, Manikyam A, Anand Kumar K, et al. Spectrum of systemic bacterial infections during febrile neutropenia in pediatric oncology patients in tertiary care pediatric center. Indian J Cancer. 2014;51:403–405.
   PubMed Web of Science ®Google Scholar
• Sood P, Seth T, Kapil A, et al. Emergence of multidrug resistant acinetobacter blood stream infections in febrile neutropenia patients with haematological cancers and bone marrow failure syndromes. J Indian Med Assoc. 2012;110:439–444.
   PubMedGoogle Scholar
• Li D, Chen Y, Zhang W, et al. Risk factors for hospital-acquired bloodstream infections caused by extended-spectrum beta-lactamase Klebsiella pneumoniae among cancer patients. Ir J Med Sci. 2014;183:463–469. Epub 2013 Dec 03.
   PubMed Web of Science ®Google Scholar
• Ye Q, Xu X, Zheng Y, et al. Etiology of septicemia in children with acute leukemia: 9-year experience from a children’s hospital in China. J Pediatr Hematol Oncol. 2011;33:e186–91. Epub 2011 May 28.
   PubMed Web of Science ®Google Scholar
• Ko HF, Tsui SS, Tse JWK, et al. Improving the emergency department management of Post-Chemotherapy sepsis in haematological malignancy patients. Hong Kong Med J. 2015;21:10–15.
   PubMed Web of Science ®Google Scholar
• Kwon JC, Kim SH, Choi JK, et al. Epidemiology and clinical features of bloodstream infections in hematology wards: one year experience at the catholic blood and marrow transplantation center. Infect Chemotherapy. 2013;45:51–61. Epub 2013 Nov 23.
   PubMedGoogle Scholar
• Nam EY, Song KH, Kim NH, et al. Differences in characteristics between first and breakthrough neutropenic fever after chemotherapy in patients with hematologic disease. Int J Infect Dis. 2016;44:4–7.
   PubMed Web of Science ®Google Scholar
• Latiff Z, Zulkifli SZ, Jamal R. Risk assessment and microbiological profile of infections in paediatric cancer patients with febrile neutropenia. Malays J Pathol. 2002;24:83–89. Epub 2003 Jul 31.
   PubMedGoogle Scholar
• Oliveira AL, de Souza M, Carvalho-Dias VMH, et al. Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2007;39:775–781.
   PubMed Web of Science ®Google Scholar
• Trecarichi EM, Tumbarello M, Spanu T, et al. Incidence and clinical impact of extended-spectrum-β-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect. 2009;58:299–307.
   PubMed Web of Science ®Google Scholar
• Sader HS, Castanheira M, Jones RN, et al. Antimicrobial activity of ceftazidime-avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013-2014). Diagn Microbiol Infect Dis. 2017;87:261–265. Epub 2017 Jan 11.
   PubMed Web of Science ®Google Scholar
• Kang CI, Chung DR, Ko KS, et al. Risk factors for infection and treatment outcome of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Ann Hematol. 2012;91:115–121. Epub 2011 May 11.
   PubMed Web of Science ®Google Scholar
• Batra U, Goyal P, Jain P, et al. Epidemiology and resistance pattern of bacterial isolates among cancer patients in a Tertiary Care Oncology Centre in North India. Indian J Cancer. 2016;53:448–451. Epub 2017 Mar 01.
   PubMedGoogle Scholar
• Pelat C, Kardas-Sloma L, Birgand G, et al. Hand hygiene, cohorting, or antibiotic restriction to control outbreaks of multidrug-resistant enterobacteriaceae. Infect Control Hosp Epidemiol. 2016;37:272–280. Epub 2015 Dec 29.
   PubMed Web of Science ®Google Scholar
• Tschudin-Sutter S, Frei R, Dangel M, et al. Rate of transmission of extended-spectrum beta-lactamase-producing enterobacteriaceae without contact isolation. Clin Infect Dis. 2012;55:1505–1511. Epub 2012 Sep 08.
   PubMed Web of Science ®Google Scholar
• van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence. 2016;8(4):460-469.
   PubMed Web of Science ®Google Scholar
• Hauck C, Cober E, Richter SS, et al. Spectrum of excess mortality due to carbapenem-resistant Klebsiella pneumoniae infections. Clin Microbiol Infect. 2016;22:513–519. Epub 2016 Feb 07.
   PubMed Web of Science ®Google Scholar
• Pouch SM, Satlin MJ. Carbapenem-resistant Enterobacteriaceae in special populations: solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies. Virulence. 2016;8(4):391-402.
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Yamamoto M, Nagao M, et al. Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-beta-lactamase-producing Escherichia coli bacteremia. Antimicrob Agents Chemother. 2015;59:5107–5113. Epub 2015 Jun 24.
   PubMed Web of Science ®Google Scholar
• Harris PNA, Peleg AY, Iredell J, et al. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial. Trials. 2015;16:24.
   Google Scholar
• Gudiol C, Royo-Cebrecos C, Tebe C, et al. Clinical efficacy of beta-lactam/beta-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in haematological patients with neutropaenia: a study protocol for a retrospective observational study (BICAR). BMJ Open. 2017;7:e013268. Epub 2017 Jan 25.
   PubMed Web of Science ®Google Scholar
• Karanika S, Paudel S, Grigoras C, et al. Systematic review and meta-analysis of clinical and economic outcomes from the implementation of hospital-based antimicrobial stewardship programs. Antimicrob Agents Chemother. 2016;60:4840–4852. Epub 2016 Jun 02.
   PubMed Web of Science ®Google Scholar